Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Centessa Pharmaceuticals (CNTA) Shares Outstanding (Weighted Average): 2020-2024

Historic Shares Outstanding (Weighted Average) for Centessa Pharmaceuticals (CNTA) over the last 5 years, with Dec 2024 value amounting to $133.2 million.

  • Centessa Pharmaceuticals' Shares Outstanding (Weighted Average) rose 1.69% to $134.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $134.1 million, marking a year-over-year increase of 1.69%. This contributed to the annual value of $133.2 million for FY2024, which is 36.42% up from last year.
  • Latest data reveals that Centessa Pharmaceuticals reported Shares Outstanding (Weighted Average) of $133.2 million as of FY2024, which was up 36.42% from $97.6 million recorded in FY2023.
  • Over the past 5 years, Centessa Pharmaceuticals' Shares Outstanding (Weighted Average) peaked at $133.2 million during FY2024, and registered a low of $85.9 million during FY2020.
  • Over the past 3 years, Centessa Pharmaceuticals' median Shares Outstanding (Weighted Average) value was $97.6 million (recorded in 2023), while the average stood at $108.5 million.
  • Data for Centessa Pharmaceuticals' Shares Outstanding (Weighted Average) shows a peak YoY soared of 36.42% (in 2024) over the last 5 years.
  • Yearly analysis of 5 years shows Centessa Pharmaceuticals' Shares Outstanding (Weighted Average) stood at $85.9 million in 2020, then rose by 9.42% to $94.0 million in 2021, then climbed by 0.61% to $94.6 million in 2022, then rose by 3.21% to $97.6 million in 2023, then surged by 36.42% to $133.2 million in 2024.